Aakash Desai/LinkedIn
Jan 9, 2025, 16:29
Aakash Desai: Rybrevant + Lazcluze to show clinically meaningful improvement in OS vs osimertinib
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared on X:
“MARIPOSA Johnson and Johnson announces Positive OS results in 1L EGFR
Amivantamab + lazertinib vs. osimertinib:
Statistically significant improvement in OS (press release states >1 yr survival benefit)
Await complete data and presentation.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 9, 2025, 16:33
Feb 9, 2025, 16:31
Feb 9, 2025, 16:27
Feb 9, 2025, 15:42
Feb 9, 2025, 15:39
Feb 9, 2025, 15:39
Feb 9, 2025, 15:35